Andrew Satlin Selected Research

lumateperone

12/2021	Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
1/2021	Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials.
1/2021	Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew Satlin Research Topics

Disease

12	Alzheimer Disease (Alzheimer's Disease) 09/2017 - 01/2002
5	Hypertension (High Blood Pressure) 12/2007 - 01/2007
4	Sleepiness 12/2021 - 11/2017
3	Seizures (Absence Seizure) 01/2019 - 08/2013
3	Dementia (Dementias) 09/2017 - 12/2004
3	Cognitive Dysfunction 01/2014 - 07/2004
2	Nausea 12/2021 - 05/2011
2	Schizophrenia (Dementia Praecox) 01/2021 - 01/2021
2	Heart Failure 01/2021 - 01/2018
2	Body Weight (Weight, Body) 01/2021 - 05/2016
2	Lennox Gastaut Syndrome 01/2019 - 05/2016
2	Parkinson Disease (Parkinson's Disease) 11/2013 - 12/2004
2	Diarrhea 05/2011 - 07/2007
1	Systolic Heart Failure 01/2021
1	Headache (Headaches) 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2018
1	Myocardial Infarction 01/2018
1	Unstable Angina 01/2018
1	Weight Loss (Weight Reduction) 01/2018
1	Stroke (Strokes) 01/2018
1	Overweight 01/2018
1	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2017
1	Epilepsy (Aura) 05/2016
1	Edema (Dropsy) 04/2016
1	Hemorrhage 04/2016
1	Meningoencephalitis 01/2014
1	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2013
1	Vomiting 05/2011
1	Diabetes Mellitus 12/2007
1	Essential Hypertension 01/2007
1	Memory Disorders (Memory Loss) 12/2004
1	Multi-Infarct Dementia (Dementia, Multi Infarct) 12/2004
1	Bipolar Disorder (Manic Depressive Psychosis) 12/2004
1	Psychotic Disorders (Schizoaffective Disorder) 12/2004
1	Disease Progression 07/2004
1	Delirium 01/2002

Drug/Important Bio-Agent (IBA)

5	Pharmaceutical PreparationsIBA 01/2021 - 07/2007
5	aliskiren FDA Link 12/2007 - 01/2007
3	lumateperoneIBA 12/2021 - 01/2021
3	Amyloid (Amyloid Fibrils)IBA 04/2016 - 01/2014
3	Antihypertensive Agents (Antihypertensives)IBA 12/2007 - 01/2007
3	Renin InhibitorsIBA 12/2007 - 01/2007
2	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 01/2021
2	rufinamide FDA Link 01/2019 - 05/2016
2	Monoclonal AntibodiesIBA 04/2016 - 01/2016
2	perampanelIBA 03/2014 - 08/2013
2	Donepezil (Aricept)FDA LinkGeneric 05/2011 - 07/2010
2	Valsartan (Vals)FDA Link 07/2007 - 01/2007
2	CreatineIBA 12/2004 - 01/2002
2	Protons (Proton)IBA 12/2004 - 01/2002
1	CholesterolIBA 01/2021
1	ProlactinIBA 01/2021
1	Risperidone (Risperdal Consta)FDA LinkGeneric 01/2021
1	LDL CholesterolIBA 01/2021
1	ITI-214IBA 01/2021
1	lorcaserinIBA 01/2018
1	omega-Chloroacetophenone (Mace)IBA 01/2018
1	5-HT2C Serotonin ReceptorIBA 01/2018
1	lemborexantIBA 11/2017
1	Orexin Receptor AntagonistsIBA 11/2017
1	VaccinesIBA 01/2014
1	lecanemabIBA 01/2014
1	AN-1792IBA 01/2014
1	Amyloid beta-PeptidesIBA 01/2014
1	Anticonvulsants (Antiepileptic Drugs)IBA 08/2013
1	AcidsIBA 08/2013
1	AMPA Receptors (AMPA Receptor)IBA 08/2013
1	Ramipril (Altace)FDA LinkGeneric 12/2007
1	ReninIBA 07/2007
1	Lisinopril (Prinivil)FDA LinkGeneric 01/2007
1	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2007
1	Inositol (Myoinositol)IBA 12/2004
1	N-acetylaspartate (N-acetyl aspartate)IBA 12/2004
1	Rivastigmine (Exelon)FDA LinkGeneric 07/2004
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 07/2004
1	Choline (Choline Chloride)IBA 01/2002
1	Paroxetine (Paxil)FDA LinkGeneric 01/2002
1	Cholinergic AgonistsIBA 01/2002
1	xanomelineIBA 01/2002

Therapy/Procedure

4	Therapeutics 01/2018 - 08/2013
2	Immunotherapy 01/2015 - 01/2014
1	Institutionalization (Institutionalized Persons) 09/2017
1	Secondary Prevention 02/2016
1	Aftercare (After-Treatment) 01/2002